Clinical trials: HPA
Stress, Trauma
Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness
The purpose of this study is to investigate justice-involved Black/African American female adolescents' (JI BAFAs; N=35) self-reported outcomes: stress, posttraumatic stress disorder (PTSD), recidivism, etc., as well as their…
- Conditions
- Stress, Trauma, PTSD, HPA
- Trial name
- NCT06311188
- Testing
- ITR Healing intervention
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Inflammation, HPA
Impacts of Cash Transfers on Child Neurodevelopment (Auxilio Brasil)
This study examines the impact of Auxilio Brasil (AB), a cash transfer program to mothers of school-age children, on resource-deprived populations in Brazil and its protective effects on child neurodevelopment and mental health.
- Conditions
- Inflammation, HPA, CBCL, Family Relations
- Trial name
- NCT05477901
- Testing
- Supplemental cash transfer
- Where
- 2 sites in United States, Brazil
- Volunteers
- 450 people
- Sponsor
- New York State Psychiatric Institute
Healthy Volunteer Study, HPA
Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function
This study aims to investigate the effects of a single dose of the glucagon-like 1 receptor agonist semaglutdie/Rybelsus on the hypothalamo-pituitary-adrenal axis, thus cortisol levels and other stresshormones in healthy males.
- Conditions
- Healthy Volunteer Study, HPA, Cortisol Deficiency, Adrenal Insufficiency
- Trial name
- PIANO (NCT06608433)
- Testing
- semaglutide
- Where
- Switzerland
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or Tetrahydrobiopterin (BH4) Deficiency
Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency
Kuvan® is a synthetic copy of a body's own substance called tetrahydrobiopterin (BH4). BH4 is required by the body to use an amino acid called phenylalanine in order to build another substance called tyrosine.
- Trial name
- KAMPER (NCT01016392)
- Where
- 69 sites in Austria, France and 7 more
- Volunteers
- 627 people
- Sponsor
- BioMarin Pharmaceutical